Plus Therapeutics (NASDAQ:PSTV) is developing its lead asset, rhenium nanoliposome (RNL), a targeted and potentially more potent radionucleotide therapy, for the treatment of recurrent glioblastoma and several other...
Closely-held Genelux expects to arrange an end-of-Phase 2 meeting with the FDA in the first quarter of 2021 and then launch a Phase 3 trial in mid-year with its Olvi-Vec vaccinia virus in combination with chemotherapy...
Izotropic (CSE:IZO; OTC:IZOZF; FSE:1R3) is developing a dedicated breast imaging system aimed at the better detection – and potentially earlier diagnosis and treatment – of breast cancer.
Kintara Therapeutics (NASDAQ:KTRA), fresh off a merger and $25-million private placement, is moving into a global registration trial in newly-diagnosed and recurrent glioblastoma multiforme (GBM), a deadly brain cancer...
After close to three decades developing its artificial intelligence platform, Hepion Pharmaceuticals (NASDAQ:HEPA) is deploying its AI-POWR machine learning platform in its clinical program to tackle non-alcoholic...
Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics.
By Leonard Zehr 9 Meters Biopharma (NASDAQ: NMTR) expects to report clinical trial data readouts in 2021 from two gastrointestinal disorders: short bowel syndrome, an underserved and debilitating rare disease, and...
Closely-held Novamind is building the infrastructure required to facilitate safe, legal and medically-supervised psychedelic-assisted therapy. “We saw an opportunity to build a sustainable business in a market that’s...
Lantern Pharma (NASDAQ:LTRN) is using its RADR AI platform to identify abandoned drug candidates and develop new drugs that may prove effective in treating certain cancers.
Monopar Therapeutics (NASDAQ:MNPR), which focuses on developing cancer therapies and treatments for cancer-related adverse events, is on track for two important clinical trials with its lead drug candidates, Validive...
aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...
Closely-held PregnanTech is completing a clinical safety study with its Lioness device to prevent preterm birth in non-pregnant women about to undergo a hysterectomy as a steppingstone to a larger proof-of-concept study...
BioCardia (NASDAQ:BCDA) is developing two late-stage clinical autologous cell therapies, known as CardiAMP, for ischemic heart failure and chronic myocardial ischemia, a neurokinin 1 receptor positive (NK1R+) allogenic...
By Leonard Zehr The University Hospital of Cologne is one of the largest in Germany with 59 departments and institutions, and is a leading interdisciplinary Oncology Center of Excellence. Recently, the interdisciplinary...
Closely-held clinical metagenomics company, IDbyDNA, is commercializing its Explify platform with the goal of replacing traditional pathogen detection with a data-driven approach. “Our vision is to deploy our...
Closely-held Axolotl Biosciences is developing a bioink specifically formulated for the bioprinting of neural tissue, for biotechnology and pharmaceutical companies to use for research and development purposes. “Last...
On the heels of an FDA approval, Chiasma (NASDAQ:CHMA) is preparing for the U.S. launch of MYCAPSSA, the first orally administered somatostatin analog for the long-term maintenance treatment of acromegaly in patients...
As the founder of Atlanta’s renowned Busch Center, Dr. Joseph Busch Jr. brings a 40-year-plus track record in diagnostic radiology and hundreds of international research studies to preventative screening and accurate...
Fueled by decades of research in protein dysregulation and fundamental neuroscience, Prothena (NASDAQ:PRTA) is advancing a pipeline of therapeutic candidates with the potential to change the course of diseases such as...
InspireMD (NYSE American:NSPR) is awaiting a decision from the FDA for an investigational device exemption as a steppingstone for a pivotal trial of its CE Mark-approved CGuard Carotid Stent System for the prevention of...
Soliton (NASDAQ:SOLY) has filed a 510(k) submission for FDA clearance of its Rapid Acoustic Pulse (RAP) technology for reduction in the appearance of cellulite, which affects between 80% and 90% of women. The FDA has...
NeuroOne (OTCQB:NMTC) is developing high-definition, minimally invasive thin-film electrodes for the diagnosis and treatment of various neurological conditions, including epilepsy, Parkinson’s disease (PD) and chronic...